Introduction PKR (protein kinase RNA regulated) is an interferoninduced translational regulatory protein that is found in most mammalian cells (for review: Clemens and Elia, 1997) . It is an important component of the interferon stimulated anti-viral defense mechanism of the cell. PKR is present in a latent or inactive state in cells and is activated by very low concentrations of double-stranded RNAs (dsRNAs), a few highly structured single-stranded RNAs (ssRNAs), heparin and related polysaccharides, poly (L-glutamine) and PACT, a cellular protein activator. Upon activation, PKR is autophosphorylated and phosphorylates its substrates, which include the translation initiation factor eIF2. Phosphorylated eIF2 entraps another initiation factor, eIF2B, in an inactive complex, which subsequently causes inhibition of translation (for review: Clemens and Elia, 1997). PKR also phosphorylates other proteins that are involved in the transcription pathway such as, IkB, the inhibitor of transcription factor, NF-kB (Kumar et al., 1997; Maran et al., 1994; Oermann et al., 1995) , NF90 (Langland et al., 1999; Patel et al., 1999; Parker and Mathews, unpublished data) , RNA helicase A (Parker and Mathews, unpublished data) and HIV-1 Tat (Brand et al., 1997) .
Recent studies imply that PKR plays a part in cell growth regulation (see reviews: Clemens and Elia, 1997; Williams, 1997) . Catalytically inactive mutant forms of PKR, when overexpressed, cause transformation of mouse 3T3 ®broblasts and tumorigenesis when implanted into nude mice (Koromilas et al., 1992; Meurs et al., 1993; Romano et al., 1998) . This ®nding led to the conclusion that PKR is a tumor suppressor. It is thought that mammalian cells normally have low PKR activity, therefore a small fraction of eIF2a is phosphorylated, sucient to hold the synthesis of cell growth promoting proteins in check but not to inhibit overall protein synthesis. Expression of the inactive form of PKR could exert a dominant negative eect, inhibiting PKR activity and thereby increasing the expression of regulatory proteins important for cell proliferation, resulting in uncontrolled cell division. However, the tumor suppressor role remains controversial. In support of antiproliferative eects of PKR, overexpression of wild type protein results in slow growth in yeast (Chong et al., 1992) and causes apoptosis in mammalian cells (Balachandran et al., 1998; Der et al., 1997; Donze et al., 1999; Lee et al., 1997; Yeung and Lau, 1998) . A mutant form of eIF2 that cannot be phosphorylated by PKR was also observed to transform cells (Donze et al., 1995) , as does TRBP, a cellular inhibitor of PKR (Benkirane et al., 1997) . Expression of another cellular inhibitor of PKR, p58, also transforms cells (Barber et al., 1994) . On the other hand, a p58 mutant that does not interact with or inhibit PKR has the same eect, questioning the involvement of PKR in cell transformation by p58-IPK (Tang et al., 1999) .
Inconsistent with the role of PKR as a tumor suppressor, PKR de®cient or knock-out transgenic mice are normal and do not show any signs of neoplasia (Yang et al., 1995; Abraham et al., 1999) . Furthermore, the primary ®broblast cell line derived from the PKR knock-out mouse grows slower than those derived from the normal control mouse (our unpublished observation; Zamanian-Daryoush et al., 1999) implying that PKR may be required for cell proliferation. Contrary to expectation, cell cycle studies conducted with these PKR-de®cient cell lines indicate that PKR is important for the normal passage of cells through the G1/S phase of the cell cycle (ZamanianDaryoush et al., 1999) . These observations may suggest a role for PKR as a positive growth regulator.
Few studies of PKR's role in naturally occurring cancers have been conducted, and these reports are equivocal with respect to a tumor suppressor function. In murine lymphoblastic leukemic cells (Jaramillo et al., 1995) and some human leukemic and preleukemic myeloid cells (Beretta et al., 1996) PKR expression is higher than in the corresponding normal cells as would be expected if PKR were functioning as a tumor suppressor. The observation that PKR levels in head and neck squamous carcinomas are inversely proportional to that of PCNA, may lend support to PKR being anti-proliferative (Haines et al., 1998) . On the other hand, PKR levels in human breast cancer tissues are several fold higher than in the surrounding normal epithelial cells (Haines et al., 1996) . Lymphocytes derived from human leukemic patients have levels of PKR comparable to those derived from normal control individuals (Basu et al., 1997) . Similarly, higher PKR levels are associated with well-dierentiated tumors and non-apoptotic cells of hepatocellular carcinomas (Shimada et al., 1998) . These studies provide examples of cancer cells in which PKR does not seem to function as a tumor suppressor.
One limitation of most of these studies is that they measure the levels rather than the activity of PKR. We report here a detailed study to evaluate the function of PKR in human breast cancer. Breast cancers are carcinomas resulting from an over-proliferation of epithelial cells lining the ducts or lobules of the breast. In this study, PKR activity was determined in cell lines derived from human mammary carcinomas and compared to that in nontransformed mammary epithelial cell lines. PKR activity was dramatically higher in the carcinoma cell lines, although the PKR protein levels were only a few fold higher than in the nontransformed cell lines. An inhibitor of PKR was detected in the nontransformed cell lines, which may account for the low PKR activity. Correlating with the PKR inhibitory activity, the level of P58, a previously described PKR inhibitor, is much higher in nontransformed cells than in the carcinoma cells. Furthermore, PKR and P58 coimmunoprecipitated, indicating a physical interaction of the kinase and its inhibitor in the nontransformed cell lysates. In agreement with the PKR activities observed, a greater proportion of its substrate, eIF2a, was phosphorylated in the carcinoma cell lines than in the nontransformed cell lines. However, the rate of protein synthesis in the carcinoma cells was unaected by eIF2a phosphorylation, probably due to overexpression of eIF2B.
Results

Immunohistochemical detection of PKR in mammary carcinoma cell lines
To study the role of PKR in breast cancer, we examined six cell lines derived from invasive mammary ductal cancers (MDA ± MB435, MDA ± MB468, T47D, MDA ± MB231, MCF7 and MDA ± MB453) and two nontransformed cell lines derived from mammary ductal epithelium of ®brocystic patients (MCF10A and MCF12A). An earlier immunohistochemical analysis of breast cancer tissues had indicated that PKR was expressed at high levels in carcinoma tissues as compared to the normal mammary ductal epithelial cells (Haines et al., 1996) . To determine whether similar results pertain in cell lines, we performed immunohistochemical analysis on the cell lines derived from breast carcinoma and nontransformed cells. Paran sections of the cell lines were probed for PKR using polyclonal antibody to PKR (Green and Mathews, 1992) . The results showed a higher PKR-speci®c staining in carcinoma cell lines than in the nontransformed cell lines (Figure 1 ). In fact, the signal for PKR in the nontransformed cell line was barely above that of the preimmune serum control. The chromagen staining in the carcinoma cells is blocked by PKR protein indicating that the staining is speci®c for PKR (data not shown). These results indicate that PKR expression in the breast carcinoma and the nontransformed cell lines are indeed similar to that reported in the carcinoma and the normal epithelial tissues from patients (Haines et al., 1996) . We therefore proceeded to use the cell lines for biochemical analysis of the role of PKR in breast cancer.
Elevated PKR activity in mammary carcinoma cell lines
To determine the activity of PKR in the mammary epithelial cell lines, a PKR autophosphorylation assay was performed by incubation of the cell lysate with dsRNA and g-32 P-labeled ATP, followed by immunoprecipitation of PKR using polyclonal antibody and analysis by SDS-polyacrylamide gel electrophoresis. Autophosphorylation of PKR in the lysates from carcinoma cell lines was readily detected (Figure 2A , lanes 1 ± 6) whereas PKR autophosphorylation was barely detected in lysates of nontransformed cell lines (Figure 2A, lanes 7, 8) . Since autophosphorylation leads to activation of PKR, a higher degree of autophosphorylation in the carcinoma cell lysates is indicative of higher PKR activity in these cells. In the nontransformed cells, however, there is a lack of autophosphorylation and therefore a lack of PKR activity. In addition, the antibody speci®c for phosphorylated-PKR (Biosource, Inc.) recognized PKR in carcinoma cells, but not in nontransformed cells ( Figure 2C , compare lanes 2, 3) indicating that at least a portion of the PKR in carcinoma cells is autophosphorylated and active, while in the nontransformed cells the enzyme is primarily unphosphorylated and inactive. Quantitation of the kinase assay indicates that PKR in the carcinoma cell lines is 7 ± 40-fold more active than that in nontransformed cell lines ( Figure 2B ). therefore, PKR activity seems to correlate with the expression levels of the enzyme in the cell line as determined by immunohistochemistry (Figure 1 ). However, these results are surprising and dicult to reconcile with the notion that PKR is a tumor suppressor.
eIF2a phosphorylation is elevated in mammary carcinoma cell lines
To measure PKR activity directly, an eIF2a phosphorylation assay was performed. The kinase assay was done in the presence of puri®ed human eIF2, followed by immunoprecipitation with both PKR antibody and eIF2a antibody. The nontransformed cell lysates did not show phosphorylation of either PKR or eIF2a ( Figure 3A , lanes 7, 8). These results con®rm that little, if any, PKR activity is detectable in the nontransformed cell lines. However, PKR is autophosphorylated and eIF2a is phosphorylated by carcinoma cell lysates (lanes 1 ± 6), albeit to varying degrees.
To determine whether eIF2a phosphorylation by carcinoma cell lysates is dsRNA dependent, the same assay was performed in the presence or absence of dsRNA ( Figure 3B ). Puri®ed PKR from the transformed human embryonic kidney cell line, 293, gave rise to two radioactive bands of autophosphorylated PKR and phosphorylated eIF2a (lane 5). When the MCF7 mammary carcinoma cell lysate was assayed for eIF2a phosphorylation in the absence of dsRNA, eIF2a was phosphorylated to a very small extent (lane 4), which increased several fold in the presence of dsRNA (compare lanes 3, 4). In contrast, nontransformed MCF12A cell lysate showed no eIF2a phosphorylation in the presence or absence of dsRNA (lanes 1, 2).
Since the activity of PKR is high in carcinoma cell extracts, it would be expected that the endogenous substrates of PKR would be phosphorylated. We determined the phosphorylation state of eIF2a by vertical isoelectric focusing gel electrophoresis. This technique allows the separation of the phosphorylated and unphosphorylated forms of the protein, which can be visualized by Western blot analysis. Reticulocyte lysate incubated in the absence of hemin, which leads to Figure 1 Immunohistochemical analysis for PKR expression in mammary carcinoma cell lines and nontransformed cell lines eIF2a phosphorylation, was used as a marker for the positions of the phosphorylated and unphosphorylated eIF2a ( Figure 3C, lane 7) . In carcinoma cell lysates 10 ± 40% of eIF2a is phosphorylated (lanes 3 ± 6), whereas less than 2% of eIF2a is phosphorylated in nontransformed cell lysates (lanes 1, 2). This suggests that PKR is active and phosphorylates eIF2a in mammary carcinoma cells, whereas almost all the eIF2a in the nontransformed cell lines is present in an unphos-phorylated state, re¯ecting the low PKR activity.
PKR phosphorylates eIF2a on serine , Western blot analysis was performed using antibody speci®c for serine 51 phosphorylated eIF2a. The results show that the level of phosphorylated form of eIF2a is about eightfold higher in the carcinoma cell line MCF7 than in the nontransformed cell line MCF12A ( Figure 3D , upper panel), although the level of total eIF2a in MCF7 cells is only about twofold higher than in MCF12A cells ( Figure 3D , lower panel and Figure 3C , compare lanes 1, 3). This is consistent with the results from the vertical isoelectric focusing gel electrophoresis ( Figure  3C ) suggesting that PKR is active and eIF2a is phosphorylated in carcinoma cells, whereas in the nontransformed cell lines PKR is mostly inactive and therefore the eIF2a is mostly unphosphorylated.
Higher levels of eIF2B subunits in breast carcinoma cell lines
The initiation factor eIF2B has a high anity for phosphorylated eIF2, so that the phosphorylated eIF2 entraps eIF2B in an inactive complex, thereby depleting the system of eIF2B leading to inhibition of initiation of translation and shut down of protein synthesis (Clemens and Elia, 1997). The high level of eIF2a phosphorylation in breast carcinoma cell lines would be expected to reduce the rate of protein synthesis in these cells. However, the rate of protein synthesis in the carcinoma cell lines is similar to that of nontransformed cell lines (data not shown), indicating that the protein synthesis machinery of the carcinoma cells is tolerant to eIF2a phosphorylation. Recently Hinnebusch's laboratory has demonstrated that, in yeast, overexpression of eIF2B or its three regulatory subunits can render the organism insensitive to the adverse eects of phosphorylated eIF2a on protein synthesis and cell growth (Pavitt et al., 1998) . Furthermore, the inhibition of protein synthesis in a cell free system can be overcome by excess eIF2B (Reichel et al., 1985) . The level of the subunits of eIF2B in the breast epithelial cell lines were determined by Western blot analysis using antibody to the subunits of eIF2B (Old®eld et al., 1994) to investigate if the breast cancer cells utilize this mechanism to neutralize the eects of phosphorylated eIF2. The results showed that the a and b subunits, two of the three regulatory subunits of eIF2B, were present in higher levels in the carcinoma lysates than in the nontransformed cell lysates ( Figure 3E , compare lanes 4 ± 7 with lanes 2, 3). Lane 1 contains puri®ed eIF2B as a control. Similarly, subunit g, the accessory subunit of the catalytic subunit e, was also higher in carcinoma cell lysates (data not shown). When normalized to actin levels, it is apparent that the subunits of eIF2B are indeed more highly expressed in carcinoma cell lines than in the nontransformed cell lines. These results indicate that eIF2B is overexpressed in breast cancer cell lines and may explain their tolerance to eIF2 phosphorylation, which is a direct consequence of high PKR activity.
Low specific activity of PKR in nontransformed breast cell lines PKR was virtually undetectable in nontransformed cell lines by immunohistochemical analysis (Figure 1 ) and its activity is greatly reduced (Figures 2 and 3) . To determine whether its activity is directly proportional to the PKR protein levels, we performed Western blot analysis on the cell lysates using PKR polyclonal antibody. PKR protein was detectable in all the cell lines; its concentration was modestly lower (2 ± 4-fold) Figure 4B ). Two conclusions can be drawn. First, the detection of PKR is poor in the nontransformed cell lines by immunohistochemical analysis even though the level of the protein is only a few fold lower than that in the carcinoma cells where PKR shows a strong chromagen staining. Second, PKR activity is still higher in carcinoma cell lines (5 ± 20-fold) than that in nontransformed cell lines even when normalized to the PKR protein levels ( Figure  4C ). It is therefore apparent that the dierence in protein level (2 ± 4-fold) only partially accounts for the 7 ± 40-fold dierence in PKR activity between the carcinoma and nontransformed cell lines (Figure 2 ).
Nontransformed mammary epithelial cells contain an inhibitor of PKR
We considered two possible reasons for lower speci®c activity of PKR in nontransformed cell lines: (1) the carcinoma cell lines may contain an activator of PKR, and (2) the nontransformed cell lines may contain an inhibitor of PKR. To investigate these possibilities, we performed a mixing experiment. The lysates of carcinoma cells and the nontransformed cells were mixed and preincubated for 10 min before PKR activity was assayed. If the carcinoma cell lysate contained a PKR activator, mixing should cause an increase in autophosphorylation of PKR because of the activation of PKR in the nontransformed cell lysate. On the other hand, if nontransformed cell lysate contained an inhibitor, the autophosphorylation of PKR should be diminished. As shown in Figure 5A , the PKR activity in MCF7 cell lysate was decreased by mixing and preincubation with MCF10A lysate in a dose dependent manner (compare lane 1 with lanes 2 ± 5). This indicates that MCF10A lysate contains an inhibitory component that blocks the activation of PKR in MCF7 lysate. Similar results were obtained in mixing experiments using lysates from MCF12A (nontransformed cell line) and T47D and MDA ± MB468 (carcinoma cell lines) (data not shown) indicating that both the nontransformed cell lysates Figure 3 Phosphorylation of eIF2a and levels of eIF2B are higher in mammary carcinoma cell lines. (A) PKR activation assay was performed as described in Figure 1A in the presence of puri®ed human eIF2 using lysates of carcinoma (C) (lanes 1 ± 6) or nontransformed (N) (lanes 7, 8) cell lines and immunoprecipitated using both PKR antibody and eIF2a antibody and analysed as described in Materials and methods. (B) Phosphorylation of eIF2a by carcinoma cell lysate is dsRNA dependent. PKR assays with eIF2 was performed and analysed as described in (A) were performed in the presence (+) or absence (7) of dsRNA. Puri®ed PKR was used as a control (lane 5). (C) Endogenous eIF2a is phosphorylated in mammary carcinoma cell lines and not in nontransformed cell lines. Lysates from carcinoma (C) (lanes 3 ± 6) or nontransformed (N) (lanes 1, 2) cells were subjected to vertical gel isoelectric focusing electrophoresis, blotted onto an immobilon membrane and probed with eIF2a antibody as described in the Materials and methods. Positions of phosphorylated (eIF2aP) and nonphosphorylated eIF2a are marked. (D) Western blot analysis of lysates from carcinoma cells MCF7 or nontransformed cells MCF12A probed with either phospho-serine51 eIF2a antibody (top panel) or total eIF2a antibody (bottom panel). (E) Levels of eIF2B subunits are higher in carcinoma cell lines than in nontransformed cell lines. 50 mg protein from carcinoma cell lysates carcinoma (C) (lanes 4 ± 7) and nontransformed cell lysates (N) (lanes 2, 3) were run on a SDS ± polyacrylamide gel and subjected to Western blot analysis using antibodies to a or b subunits of eIF2B. Lane 1 contains puri®ed rabbit eIF2B as a positive control. The blot was also probed with actin antibody as a control for loading tested contain a PKR inhibitor. The fact that PKR activity in the carcinoma cells can be inhibited suggests that PKR in these cells is a wild type protein and not a constitutively active mutant.
Activation of puri®ed PKR from interferon induced 293 cells was also inhibited in the presence of MCF10A lysate (data not shown). The inhibitory activity is present in the post-ribosomal supernatant fraction and is not associated with the ribosomal pellet (data not shown). The level of PKR in the MCF7 lysate was not diminished after the mixing reaction with MCF10A lysate as evident by Western blot analysis ( Figure 5B) , indicating that the inhibitory activity is not due to proteolytic degradation of PKR. MCF10A lysate failed to dephosphorylate previously-activated/autophosphorylated PKR (data not shown), indicating the inhibition is not due to a phosphatase activity. The inhibitory activity was lost upon heat treatment and phenol extraction, but was insensitive to RNase digestion, suggesting that it is due to a protein. We therefore generated antibody against the PKR inhibitor, p58, and examined cell extracts for the levels of this protein by Western blot analysis using puri®ed polyclonal antibody to GST-p58. As shown in Figure  5C , the level of p58 is high in both the nontransformed cell lysates and barely detected in the carcinoma cell lysates (compare lanes 1 ± 4 with lanes 5,6). The level of p58 correlates with the PKR inhibitory activity observed in the nontransformed cell lysates.
P58 interacts directly with PKR, preventing its activation by blocking dimerization and autophosphorylation (Polyak et al., 1996) . To determine if PKR and P58 interact in the nontransformed cell lysate, we investigated whether PKR can be coimmunoprecipitated with anti-P58. Proteins immunoprecipitated from lysates by P58 antibody were analysed for the presence of PKR by Western blot analysis using PKR monoclonal antibody. PKR was detected in the P58 immunoprecipitate from nontransformed cell MCF12A lysate ( Figure 5D , lane 1) indicating an interaction between the two proteins in these cells. As expected, in the carcinoma cell lysate, which does not contain detectable levels of P58, PKR could not be detected in the p58 immunoprecipitate (lane 3). However, when the two lysates were mixed, a larger amount of PKR was coimmunoprecipitated (lane 2), presumable because of the increased quantity of PKR in the mixture. Similar results were obtained when radiolabeled PKR was added to the lysates before P58 immunoprecipitation was performed. Figure 5E shows that labeled PKR was detected in the immunoprecipitate from MCF12A lysate, indicating that P58 is interacting with PKR in the nontransformed cell lysate. Labeled PKR was not coimmunoprecipitated by P58 antibody from the carcinoma cell MCF7 lysate due to the lack of P58 in these cells. These results indicate that PKR and its inhibitor P58 physically interact, strongly suggesting that P58 is responsible for 
Discussion
The role of PKR in cell growth regulation is controversial, with some studies supporting a tumor suppressor function and others suggesting a growthpromoting role. However, it is possible that the function of PKR varies with the type of cancer in question. Here we report that the breast carcinoma cell lines have higher PKR activity, higher PKR protein levels, and higher levels of phosphorylated eIF2 than the nontransformed epithelial cell lines. In addition, the nontransformed cell lines contain p58, an inhibitor of PKR that interacts with PKR in these cells and may be responsible for their low PKR activity. All of these observations indicate that PKR does not function as a tumor suppressor in breast cancer cells, and instead suggest that it exerts a positive role in cell growth control.
PKR, because of its ability to phosphorylate eIF2, is a potent inhibitor of protein synthesis. However, the rate of protein synthesis of carcinoma cell lines is not aected by its high PKR activity. Earlier reports have indicated that higher levels of eIF2B can overcome the inhibitory eects of eIF2 phosphorylation on protein synthesis (Pavitt et al., 1998; Reichel et al., 1985) . Similarly, we observed that breast carcinoma cell lines overproduce eIF2B, possibly to negate the adverse eects of PKR on protein synthesis. This suggests that the function of PKR in the carcinoma cells is not realized through regulation of protein synthesis.
The high PKR activity in mammary carcinoma cell lines may point to a role in promotion of tumorigenesis of breast cancer cells, which, in nontransformed cells, is kept under check by the PKR inhibitor, possibly p58. was immunoprecipitated using anti-P58 and analysed for PKR by Western blot analysis using PKR monoclonal antibody. MCF12A lysate was also analysed using protein A-sepharose with no antibody as a negative control (lane 4). (E) Coimmunoprecipitation of radiolabeled PKR using P58 antibody from nontransformed cell lysate. Puri®ed PKR was radiolabeled in a kinase reaction in vitro, and mixed with lysate (100 mg protein) of MCF12A (lane 2) or MCF7 (lane 3) before immunoprecipitating with anti-P58 bound protein A-sepharose as described in Materials and methods. Lane 1 contains 20% of the radiolabeled PKR that was mixed with the lysates before immunoprecipitation. Lanes 4 and 5 are no lysate and no antibody negative controls, respectively
Higher PKR activity and levels have also been observed in human melanoma cell lines as compared to normal cultured melanocytes (unpublished observation). In addition, human colon cancer cell lines demonstrate a very high level and activity of PKR (unpublished observation). As mentioned above, PKR de®cient mouse cells grow slower than the normal control cells (our unpublished observation and Zamanian-Daryoush et al., 1999) , and inhibition of PKR leads to stalling in G1/S phase of the cell cycle (Zamanian-Daryoush et al., 1999) . These ®ndings suggest a requirement for PKR in cell proliferation.
The mechanism by which PKR functions to promote cell growth and proliferation is unknown. It has been implicated in signal transduction pathways, such as PDGF mediated pathway that leads to cell proliferation. (Mundschau and Faller, 1995) . The high PKR activity in breast cancer cells may activate protooncogenes through such pathways that are required for induction or sustenance of cell proliferation. Since PKR is also a potent inhibitor of translation, the breast carcinoma cells have evolved a mechanism to block its eect on protein synthesis by overproducing eIF2B, so as to be able to exploit the positive role of PKR on cell growth and proliferation.
Materials and methods
Cell lines
Six mammary carcinoma cells lines (MDA ± MB435, MDA ± MB468, T47D, MDA ± MB231, MCF7 and MDA ± MB453 from ATCC) and two nontransformed mammary epithelial cell lines (MCF10A and MCF12A from ATCC) were grown as monolayers in 10 cm plates as per the ATCC recommended protocol. Subcon¯uent plates of cells were used for all the experiments.
Cell lysis
Cells from one subcon¯uent plate were harvested and suspended in 100 ml of homogenization buer containing 20 mM HEPES ± KOH (pH 7.4), 10 mM KCl, 15 mM MgCl 2 , 0.1 mM EDTA, 1 mM DTT, 1 mg/ml each of aprotinin, leupeptin and pepstatin, and 1 mM PMSF. The suspension was transferred to an Eppendorf tube and left on ice for 20 min. Then the suspension was homogenized in the same tube using a Kontes pellet pestle motor and disposable plastic pestle for 2 min, followed by a break for 2 min to allow cooling, and then again homogenized for 2 more minutes. The homogenate was centrifuged at 10 000 r.p.m. for 5 min in a refrigerated Eppendorf centrifuge. The supernatant was collected and the concentration of KCl adjusted to 100 mM. The lysate was frozen at 7708C till use.
PKR assays
PKR activity in the lysate was assayed by Kinase-IP assay as described previously (Gunnery and Mathews, 1998) . PKR in the lysate (prepared by non-detergent lysis) was ®rst activated and radiolabeled in a kinase reaction, then immunoprecipitated for analysis. Reactions contain, in a volume of 50 ml: 15 mM HEPES ± KOH (pH 7.4), 5 mM MgCl 2 , 1 mM DTT, 10 mg/ml each of leupeptin, pepstatin and aprotinin, 10 mM PMSF, 100 mM ATP, 0.5 mCi/ml g-32 P-ATP, 20 ng/ml of dsRNA, and 25 ± 50 mg of protein from the lysate. To determine the activity of PKR in the cell lysate without prior activation, dsRNA was omitted. The reaction was incubated at 308C for 20 min. PKR from the reaction was immunoprecipitated using polyclonal antibody (obtained as described by Green and Mathews (1992) . The polyclonal antibody was added to the reaction, which was placed on ice for 1 h, followed by addition of 50 ml of 10% (v/v: 0.043 g in 1.5 ml) protein A-Sepharose in NET 2+ buer containing 2 mg/ml of BSA. This mixture was rocked for 30 min in the cold. The protein A-Sepharose beads were washed with 1 ml NET 2+ buer about six times. After the last wash, the beads were boiled in Laemmli sample buer (Laemmli, 1970) for 15 min, centrifuged at low speed and the supernatant analysed by SDS ± polyacrylamide gel electrophoresis and autoradiography.
eIF2a phosphorylation assay
Puri®ed human eIF2 (kindly provided by JWB Hershey, University of California, Davis, USA) was included in the kinase reaction and its phosphorylation was monitored by immunoprecipitation with eIF2a speci®c monoclonal antibody (kindly provided by MJ Clemens, using eIF2a antibodyproducing ascites cells from late Henshaw's laboratory).
Vertical slab gel isoelectric focusing
To analyse the phosphorylation state of eIF2a the cell lysate was subjected to vertical slab gel isoelectric focusing by the method described by Savinova and Jagus (1997) with the following modi®cations. The lysate was lyophilized to dryness then dissolved in 50 ml of sample buer before loading on the gel. The gel was run at 2 mA with voltage maximum set at 800 V for 18 h, then for another 6 h at a voltage maximum set at 1200 V. The gel was then blotted onto immobilon membrane using a wet transfer apparatus and probed for eIF2a using monoclonal antibody.
Western blot analysis
Lysate (25 or 50 mg) was run in a SDS ± polyacrylamide gel and blotted onto PVDF immobilon membrane using the Biorad semi-dry blotting apparatus. The blot was probed using the relevant antibody, and ECL kit from ICN was used for detection. Polyclonal antibody to puri®ed human PKR was raised in rabbits (Green and Mathews, 1992) ; monoclonal antibody to human PKR was obtained from Ribogene, Inc.; polyclonal antibody to PKR phospho-peptide (T258) was obtained from Biosource, Inc.; monoclonal antibody to human eIF2a was a generous gift from Dr MJ Clemens, polyclonal antibody to phospho-serine51 eIF2a peptide was purchased from Research Genetics, Inc.; antibodies to eIF2B subunits was kindly provided by Dr Chris Proud (Old®eld et al., 1994) ; monoclonal antibody to a-actin was obtained from ICN. Polyclonal antibody to bacterially expressed GST-p58 was raised in rabbit. The p58-speci®c antibody was puri®ed from the serum using GST-bound glutathione-Sepharose and GST-p58-bound glutathione-Sepharose columns (Harlow and Lane, 1988) .
Co-Immunoprecipitation assay
Cell lysate (100 mg protein) was rocked in the presence of anti-P58 bound protein A-Sepharose for 1 h at 48C. The unbound proteins were washed, and bound proteins were analysed for the presence of PKR by Western blot analysis using monoclonal antibody to human PKR (Ribogene, Inc.) as described by Polyak et al. (1996) . When the assay was performed using radiolabeled PKR, a standard kinase assay was performed using puri®ed PKR in the presence of g-32 P-ATP (Gunnery and . The reaction was mixed with cell lysate (100 mg protein) and rocked in the presence of anti-P58 bound protein A-Sepharose for 1 h at 48C. The bound proteins were analysed by SDS ± polyacrylamide gel electrophoresis and radiolabeled PKR detected by autoradiography.
Immunohistochemical analysis
Cells from subcon¯uent 10 cm plate of cell culture were collected by gently scraping o the plates into phosphate buered saline (PBS) and pelleting by low speed centrifugation. Cells were resuspended and ®xed for 5 h in phosphate buered formaline and then embedded in paran blocks. Blocks were cut into 3.5 mm-thick sections and mounted on glass slides. After deparanation, the samples were rehydrated and then boiled in citrate buer (Antigen Retrieval Citra, BioGenex Laboratories, Inc., San Raman, CA, USA) for 10 min. After cooling, they were washed in PBS and blocking buer containing 1% BSA, 0.2% skim milk, 0.3% Triton X-100 in PBS. PKR was detected using polyclonal antibody to PKR at a dilution of 1 : 500. Preimmune rabbit serum was used as a control. Super Sensitive Detection Kit (BioGenex) was used for the subsequent steps for antigens detection using biotinylated secondary antibody, alkaline phosphatase-conjugated streptavidin, and Fast Red as the chromagen. Slides were lightly counterstained with hematoxylin for nuclear staining.
